FMC Conference Call Summary Company Overview - **Company**: FMC Corporation (NYSE:FMC) - **Industry**: Agricultural Chemicals Key Points Strategic Pathways - FMC is exploring two strategic pathways: - **Plan A**: Focus on organic growth, debt reduction, and restructuring manufacturing footprint, alongside new product development including Rynaxypyr [2][3] - **Plan B**: Considering strategic options for potential sale or merger, with interest from 5 to 10 parties [3][21] Product Pipeline and Development - FMC has four new molecules in development, with two fungicides expected to enter the market by 2030 [8][10] - The focus is shifting towards SDHI fungicides and a more diverse portfolio of pesticides and biological products [10][12] - Rynaxypyr is expected to face competition from generics, but FMC anticipates significant volume growth starting in 2026 due to broader market penetration [94][117] Financial Strategy - FMC is refinancing $500 million in debt due in October, with plans to address this through public market offerings [44][60] - The company aims to reduce overall debt levels significantly while maintaining operational flexibility [60][64] Market Impact and Risks - Current geopolitical conflicts, particularly in Iran, have not significantly impacted FMC's costs, but logistics have been affected [61][74] - If conflicts persist, raw material costs and operational expenses may rise, impacting profitability [73][81] Licensing and Sales - FMC is in the process of selling its business in India, valued at $450 million, and is also negotiating licensing for one of its new molecules [228][241] - Licensing is seen as a way to increase market reach without cannibalizing existing sales, with potential revenues from licensed products expected to enhance overall sales [275][294] Future Outlook - FMC expects a transformation in earnings by the second half of 2027, driven by the stabilization of Rynaxypyr and growth from new molecules [203][220] - The company is confident in maintaining flat earnings from 2025 to 2026 while preparing for future growth [208][220] Competitive Landscape - FMC's market share is approximately 7%, and the company aims to leverage partnerships to access broader markets [277][283] - The competitive landscape for Rynaxypyr is expected to evolve, with FMC focusing on high-quality products to maintain pricing power [137][145] Conclusion - FMC is strategically positioned to navigate current challenges while focusing on growth through innovation, licensing, and operational efficiency. The company is optimistic about its future prospects, particularly with the anticipated growth of its new product pipeline starting in 2026.

Core Viewpoint - FMC Corporation's stock has significantly declined following poor Q3 earnings and continued challenges in Q4, leading to a cautious outlook for investors [1][2]. Financial Performance - Q3 earnings revealed a 49% drop in sales, resulting in a loss of $4.52 per share, and a full-year revenue decline of 18% in 2025 [1][5]. - Q4 earnings missed revenue expectations, with management forecasting a further 5% decline in revenue to approximately $3.7 billion in 2026 and a 41% decline in adjusted EBITDA [2][8]. Stock Performance - Since the Q3 earnings report, FMC stock has stabilized, trading between $13 and $17, currently priced around $14.50 [3][8]. - The market capitalization of FMC is approximately $1.8 billion, with a current price-to-free cash flow ratio of 30 times, indicating a potentially expensive valuation given the debt load [8][9]. Strategic Options - FMC is exploring strategic options to maximize shareholder value, including the potential sale of the company [6]. - The company plans to raise $1 billion through asset sales and licensing agreements to reduce its debt, which currently exceeds cash by $3.5 billion [6]. Product Development - FMC is set to commercialize four new herbicides and fungicides, which may contribute to future revenue growth [7].

Financial Data and Key Metrics Changes - In Q4 2025, the company reported sales of $1.08 billion, an 11% decline year-over-year, or a 5% decline on a like-for-like basis excluding India [17] - Adjusted EBITDA for Q4 was $280 million, down 17% year-over-year, and adjusted EPS was $1.20, a 33% decline [18] - Free cash flow for Q4 was $623 million, with GAAP cash from operations of $657 million, up $230 million from the prior year [18][19] - The company ended 2025 with net debt of approximately $3.5 billion, down over $550 million from the third quarter [19] Business Line Data and Key Metrics Changes - Sales of the core product portfolio, excluding Rynaxypyr, were approximately $2.2 billion in 2025, with nearly $1 billion from high-cost facilities [9] - Rynaxypyr sales were just over $800 million in 2025, with expectations for generic offerings beginning in 2026 [10] - Sales of new active ingredients increased from approximately $130 million in 2024 to approximately $200 million in 2025, but fell short of the $250 million expectation [11] Market Data and Key Metrics Changes - The company faced intense competition from generics, particularly impacting pricing and sales in Latin America [17] - The removal of India from the portfolio is expected to represent a 2% full-year headwind, impacting only the first half of 2026 [12] - The company anticipates a 5% decline in sales for Q1 2026 compared to the prior year, driven by pricing headwinds and the removal of India [14] Company Strategy and Development Direction - The company is focused on strengthening its balance sheet by targeting over $1 billion in debt reduction through asset sales and licensing agreements [8] - A strategic review has been initiated to explore options, including a potential sale of the company, while continuing to sell the India commercial business [6][8] - The company aims to improve the competitiveness of its off-patent portfolio and drive growth of new active ingredients [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth portfolio, particularly the four new active ingredients, which are expected to exceed $2 billion in sales by 2035 [11][24] - The company anticipates 2026 to be a bottom year, with growth expected to resume in 2027 and 2028 [62] - Management acknowledged challenges in the core portfolio outside of Rynaxypyr, which has been impacted by generics, but remains confident in addressing these issues [56] Other Important Information - The company expects full-year sales for 2026 to be between $3.6 billion and $3.8 billion, down 5% at the midpoint versus the prior year [12] - Adjusted EBITDA for 2026 is expected to be between $670 million and $730 million, with a significant headwind from the legacy portfolio [12][15] Q&A Session Summary Question: Can you help us understand the contributions from different product groups to the $700 million EBITDA target? - Management noted that they do not break out profitability by product line but emphasized that the core portfolio is a significant contributor to profitability [29][30] Question: What gives you confidence in achieving mid-teens EBITDA growth in 2027 and 2028? - Management highlighted confidence in the growth portfolio and the expectation of improved competitiveness in the core portfolio by the end of 2026 [34][37] Question: Can you clarify the strategic review process and potential outcomes? - Management explained that the strategic review is separate from ongoing asset sales and is focused on maximizing shareholder value [40][43] Question: How do you plan to manage upcoming debt maturities? - Management stated that they intend to refinance $500 million in bonds maturing in October and are focused on reducing total debt by $1 billion [65][66] Question: What factors contributed to the shortfall in new product sales? - Management indicated that delays in registration and lower-than-expected direct sales in Brazil contributed to the shortfall [70][71]

Financial Data and Key Metrics Changes - In Q4 2025, FMC reported sales of $1.08 billion, an 11% decline year-over-year, or a 5% decline on a like-for-like basis excluding India [16] - Adjusted EBITDA for Q4 was $280 million, down 17% year-over-year, and adjusted EPS was $1.20, a 33% decline [17] - Free cash flow for Q4 was $623 million, with GAAP cash from operations of $657 million, up $230 million from the prior year [17][18] - The company ended 2025 with net debt of approximately $3.5 billion, down over $550 million from the third quarter [18] Business Line Data and Key Metrics Changes - Sales of the core product portfolio, excluding Rynaxypyr, were approximately $2.2 billion in 2025, with nearly $1 billion from high-cost facilities [7] - Rynaxypyr sales were just over $800 million in 2025, with expectations for generic offerings to begin in 2026 [8] - Sales of new active ingredients increased from approximately $130 million in 2024 to approximately $200 million in 2025, but fell short of the $250 million expectation [10] Market Data and Key Metrics Changes - Price declined by 6% in Q4 due to lower Rynaxypyr prices and strong competition, particularly in Latin America [16] - The company anticipates a mid-single-digit price headwind driven by Rynaxypyr in 2026 [11] - The removal of India is expected to represent a 2% full-year headwind, impacting only the first half of 2026 [11] Company Strategy and Development Direction - The board has authorized exploring strategic options, including a potential sale of the company, while focusing on operational priorities for 2026 [5][6] - The company aims to pay down over $1 billion of debt through asset sales and licensing agreements, including the sale of its India commercial business [6] - FMC is committed to improving the competitiveness of its off-patent portfolio and driving growth of new active ingredients [6][10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenging market conditions, including intense competition from generics and weaker grower margins [16] - The company expects 2026 to be a bottom year, with growth anticipated starting in 2027 [60][62] - Management expressed confidence in the growth portfolio and the ability to stabilize the core portfolio by addressing manufacturing costs [29][34] Other Important Information - The company is in active discussions regarding licensing agreements and asset sales, with a focus on maximizing shareholder value [5][6] - The strategic review process is at a preliminary stage, and the company has retained financial and legal advisors to assist [6] Q&A Session Summary Question: Contribution to EBITDA from different product groups - Management does not break out profitability by product line but emphasizes that the core portfolio is a significant contributor to profitability [25][27] Question: Drivers for mid-teens EBITDA growth in 2027 and 2028 - Growth is expected from the established growth portfolio, with confidence in the continuation of trends seen in previous years [32][35] Question: Timing of strategic review and potential sale of the company - The strategic review was initiated to explore options for increasing shareholder return and improving growth potential [37][38] Question: Confidence in understanding company challenges - Management acknowledges the core portfolio's challenges and is focused on addressing them while maintaining confidence in the growth portfolio [53][55] Question: Update on debt maturities and refinancing plans - The company plans to refinance $500 million in bonds maturing in October and is focused on reducing total debt by $1 billion [64][66] Question: Factors affecting new product revenue projections - The shortfall in new product revenue is attributed to registration delays and lower-than-expected sales in Brazil [69][70]

Core Insights - FMC Corporation announced its 2026 operational priorities, focusing on strengthening its balance sheet and exploring strategic options to enhance shareholder value [2][3][5] Financial Performance - For the fourth quarter of 2025, FMC reported revenue of $1.08 billion, a decline of 12% compared to the fourth quarter of 2024, with a 6% price decline primarily due to Rynaxypyr® [13][14] - The full year 2025 revenue was $3.47 billion, an 18% decrease from 2024, driven by a 6% price decline and competitive pressures [16][17] - Adjusted EBITDA for 2025 was $843 million, down 7% year-over-year, with favorable costs offset by price declines and the removal of India sales [18] 2026 Outlook - FMC's revenue guidance for 2026 is projected between $3.60 billion and $3.80 billion, reflecting a 5% decline at the midpoint compared to the previous year [6] - Adjusted EBITDA for 2026 is expected to be between $670 million and $730 million, a 17% decrease from the prior year [7] - Adjusted EPS for 2026 is forecasted to be between $1.63 and $1.89, a decrease of 41% compared to the previous year [7] Strategic Initiatives - The company plans to pay down $1 billion in debt through asset sales and licensing agreements, including the sale of its India commercial business [3][4] - FMC aims to improve the competitiveness of its core portfolio and manage the post-patent transition for Rynaxypyr® while advancing the commercialization of new active ingredients [3][4] Market Dynamics - The anticipated decline in revenue is attributed to lower prices and reduced orders from diamide partners, with India representing a 2% headwind [6] - Sales of new active ingredients are expected to grow significantly, projected between $300 million and $400 million, marking over 75% growth at the midpoint compared to the previous year [6]

Financial Data and Key Metrics Changes - The company reported third quarter GAAP net sales of $542 million, a 49% decrease year-over-year, primarily due to significant long-term actions taken in India [4][16] - Adjusted EBITDA was $236 million, reflecting a 17% increase year-over-year on an as-reported basis and a 23% increase on a like-for-like basis [9] - Adjusted EPS was $0.89, up 30% from the prior year, driven by higher adjusted EBITDA [9] Business Line Data and Key Metrics Changes - Excluding India, third quarter revenue was $961 million, down 4% year-over-year on a like-for-like basis, driven by a 6% price decline [5] - The company's growth portfolio increased by mid-single digits, with sales of new active ingredients nearly doubling compared to the prior year [5] - Sales in Latin America lagged by 8% year-over-year, attributed to low liquidity and pricing pressure from generics [6][8] Market Data and Key Metrics Changes - The market landscape in Latin America is challenging due to constrained credit for customers in Brazil and Argentina and increased competition from generics [3][6] - Sales improved in North America and EMEA, driven by higher volumes, including contributions from the recent launch of Isoflex™ Active in Great Britain [8] - The company observed generic pressure in Asia and to a lesser extent in North America and EMEA [8] Company Strategy and Development Direction - The company is focusing on being a pure play agricultural sciences company and has a strong pipeline of innovative technologies [3] - A strategic review of the manufacturing footprint is underway to transition production to lower-cost sources [13] - The company aims to become cost-competitive while growing a portfolio of IP-protected products that command higher margins [14] Management's Comments on Operating Environment and Future Outlook - Management expects the challenging conditions observed in Q3 to continue into Q4, with anticipated sales excluding India in the range of $1.12 billion to $1.22 billion [10] - The company is adjusting its full-year guidance to reflect lower sales and EBITDA expectations, with revenue now expected between $3.92 billion and $4.02 billion [11] - Management acknowledges the need for a disciplined approach to cost control and pricing to navigate the current market challenges [9][12] Other Important Information - Free cash flow guidance has been lowered to a range of negative $200 million to $0, driven by lower cash from operations [12][23] - The company has initiated a significant reduction in its quarterly dividend, which will reduce the funding need for the dividend by $250 million in 2026 [24] - The company is taking immediate actions to amend financial covenants to provide additional flexibility [24] Q&A Session Summary Question: Can you talk about the buckets of what's eating up that cash flow? - Management indicated that the primary issue is lower sales leading to reduced collections, compounded by liquidity constraints affecting cash sales [32][34] Question: What do you expect the sale price for the India business might be? - The estimated value of the India business is about $450 million, with strong interest from local and international companies [40][41] Question: How do you remain committed to the investment-grade rating? - Management is focused on reducing cash use for dividends to allow for debt repayment and restructuring costs, aiming to return to healthier metrics over time [49][50] Question: How much of your portfolio is reassessing production costs? - The company is starting to reassess its manufacturing portfolio, with some products being candidates for relocation to lower-cost sources [70] Question: Are you considering partnerships or acquisitions? - Management believes partnerships will be increasingly important, especially in technology, but is not currently considering selling any active ingredients close to commercialization [79][97]

FMC Corporation Conference Call Summary Industry Overview - The current market is characterized as normalized, with more controlled inventory levels compared to the previous year, indicating a more predictable demand environment [2][3] - Demand is described as softer, influenced by farm income and geopolitical situations, but is expected to remain stable [2][3] Company Performance and Guidance - FMC Corporation is maintaining its guidance for Q3 and Q4, with expectations aligning with previous earnings calls [2][3] - The company anticipates that the third quarter will unfold as expected, with September being a critical month for Latin America and preparation for North America [3] Future Outlook - Visibility for 2026 is expected to improve by the end of October, with a focus on the outcomes of the North American and Latin American seasons [4] - FMC is confident in its growth portfolio, particularly with new active ingredients like fluindapyr and isoflex, which are in high demand [5][6] Product Development and Market Strategy - FMC is focusing on a core portfolio of products, with a strong emphasis on new active ingredients and biologicals [5][6] - The company is preparing for the entry of generics in the market, particularly with rynaxapyr, and believes it is well-positioned for this transition [7] Regulatory Environment - The situation in India is not seen as a template for other markets due to its unique complexities, and FMC is adapting its strategy accordingly [8][9] - In the EU, there is a push from growers for new active ingredients due to a lack of available tools, which may lead to regulatory changes [17][20] Innovation and Technology - FMC is betting on new technologies and has a robust pipeline of new products, including four new active ingredients and five biologicals [9][39] - The company is actively involved in precision agriculture and is adjusting its product labels for drone applications to enhance farmer efficiency [30][31] Market Challenges - Selling new technology to growers is challenging, especially in a market where no new products have been introduced for decades [13] - The company acknowledges the need for extensive training of the sales force to effectively promote new products [13][16] Conclusion - FMC Corporation is positioned for growth with a strong product pipeline and a focus on innovation, while navigating a complex regulatory landscape and market dynamics [39][40]

Core Insights - FMC's earnings for Q2 2025 were reported at 53 cents per share, a decrease from $2.35 in the same quarter last year, but adjusted earnings per share of 69 cents exceeded the Zacks Consensus Estimate of 59 cents [2][3] - Revenues for the quarter reached approximately $1.05 billion, reflecting a 1.2% increase year-over-year and surpassing the Zacks Consensus Estimate of $965.4 million [2][3] Revenue Drivers - The increase in revenues was primarily driven by a 6% rise in volume, although prices fell by 3%, largely due to reductions in specific "cost-plus" contracts [3] - Foreign exchange rates negatively impacted results by 1% [3] Regional Sales Performance - North America: Sales decreased by 5% year-over-year to $321 million, influenced by reduced volumes in Canada despite strong growth in the U.S. [4] - Latin America: Sales increased by 1% year-over-year to $310 million, benefiting from new active ingredients, surpassing the consensus estimate [5] - Asia: Revenues declined by 17% year-over-year to $159 million, missing the consensus estimate due to lower pricing and reduced volume [5] - EMEA: Experienced a significant 29% year-over-year sales increase to $260 million, driven by volume increases in herbicides and branded products, exceeding the consensus estimate [6] Financial Position - At the end of the quarter, FMC had cash and cash equivalents of $438.2 million and long-term debt of approximately $3.27 billion [7] Guidance - FMC expects full-year revenues (excluding India) to range between $4.08 billion and $4.28 billion, indicating a 2% decline at the midpoint compared to 2024 [8] - Adjusted EBITDA is forecasted between $870 million and $950 million, suggesting 1% growth at the midpoint [8] - Adjusted earnings per share are projected to be between $3.26 and $3.70, indicating no change at the midpoint year-over-year [8] Market Sentiment - There has been an upward trend in fresh estimates for FMC, with the stock currently holding a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [10][12]

Core Insights - FMC Corporation reported earnings of 53 cents per share for Q2 2025, a significant decrease from $2.35 in the same quarter last year. Adjusted earnings per share were 69 cents, surpassing the Zacks Consensus Estimate of 59 cents [1][9] - Revenues for the quarter reached $1,050.5 million, reflecting a 1.2% increase year-over-year and exceeding the Zacks Consensus Estimate of $965.4 million [1][9] Revenue Drivers - The increase in revenues was primarily driven by a 6% rise in volume, as customers reached desired inventory levels. However, prices fell by 3%, largely due to reductions in specific "cost-plus" contracts, and foreign exchange rates negatively impacted results by 1% [2] - Sales from the growth portfolio increased by a high single-digit percentage, while sales from the core portfolio remained largely unchanged [2] Regional Sales Performance - North America: Sales declined by 5% year-over-year to $321 million, with strong growth in branded products in the U.S. offset by reduced volumes in Canada [3] - Latin America: Sales increased by 1% year-over-year to $310 million, benefiting from strong growth in new active ingredients, surpassing the consensus estimate [4] - Asia: Revenues decreased by 17% year-over-year to $159 million, driven by lower pricing and reduced volume due to destocking in India, missing the consensus estimate [4] - EMEA: Sales increased by 29% year-over-year to $260 million, fueled by significant volume increases, particularly in herbicides and branded products, exceeding the consensus estimate [5] Financial Overview - At the end of the quarter, FMC had cash and cash equivalents of $438.2 million and long-term debt of $3,270 million [6] Guidance - FMC expects full-year revenues (excluding India) to range between $4.08 billion and $4.28 billion, indicating a 2% decline at the midpoint compared to 2024. Adjusted EBITDA is forecasted between $870 million and $950 million, suggesting 1% growth at the midpoint. Adjusted EPS is projected to be between $3.26 and $3.70, indicating no change year-over-year at the midpoint [7] Price Performance - FMC's shares have decreased by 29.2% over the past year, contrasting with a 1.7% increase in the industry [10]

Q2 2025 Performance - Revenue increased by 1% to $1,051 million compared to Q2 2024[6], with organic revenue up by 2%[8, 20] - Adjusted EBITDA increased by 2% to $207 million[6, 9] - Adjusted EPS increased by 10% to $0.69[6] - GAAP Net Income decreased by 77% to $67 million[6] - GAAP EPS decreased by 77% to $0.53[6] Regional Performance - North America revenue decreased by 5% to $321 million[21] - Latin America revenue decreased by 17% to $159 million[21] - Asia revenue increased by 1% to $310 million[21] - EMEA revenue increased by 29% to $260 million[21] Financial Outlook - FY 2025 revenue is projected to be between $408 billion and $428 billion, a decrease of 2% year-over-year[24] - FY 2025 Adjusted EBITDA is projected to be between $870 million and $950 million, an increase of 1% year-over-year[24] - FY 2025 Adjusted EPS is projected to be between $326 and $370, flat year-over-year[24] - Q3 2025 revenue is projected to be between $1 billion and $110 billion, a decrease of 1% year-over-year[26] - Q3 2025 Adjusted EBITDA is projected to be between $210 million and $250 million[26] - Q3 2025 Adjusted EPS is projected to be $078 to $098, an increase of 28% year-over-year[26]